This product page is intended for qualified business, laboratory, or research-related inquiry. Availability and permitted use depend on destination country and local regulations.
Confirm product name, preferred specification, quantity, and packaging requirement before quotation.
Ask for available specification sheet, packaging details, or product-related quality documentation.
Use Inquiry Cart or the quote form so our team can reply with availability, lead time, and shipping communication.
Survodutide (also known as BI 456906) is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, jointly developed by Boehringer Ingelheim and Zealand Pharma, and is intended to treat metabolic diseases such as obesity and non-alcoholic steatohepatitis.
Survodutide is a drug with an innovative mechanism of action and is expected to become a potential option for the treatment of obesity and metabolic-related diseases. Multiple clinical studies are underway to evaluate its safety and efficacy.
Request a Quote
Send your quantity, destination country, and preferred contact method. Our team will reply with availability and quotation details.